Intralytix Signs Multiple Project Collaboration Agreement with Procter & Gamble

PRESS RELEASE - 09/21/2011

Baltimore, Maryland, U.S.A. - September 21, 2011 - Intralytix, Inc. announced today that it has entered into a Multiple Project Collaboration Agreement ("MPCA") with The Procter & Gamble Company (NYSE:PG).

"The MPCA sets the stage for Intralytix and P&G to collaborate on the development of bacteriophage (or phage) based technology for a range of applications," stated John Woloszyn, Intralytix's CEO. "Our phage-based technology is all natural and environmentally friendly and we look forward to this collaboration bringing forth new innovations," Mr. Woloszyn added.

Mr. Woloszyn also noted that the company already has two FDA/USDA approved phage-based products on the market: ListShield™, effective at substantially reducing or eliminating Listeria monocytogenes on food products, and EcoShield™, effective at substantially reducing or eliminating E. coli O157:H7 on red meat intended for grinding.

Intralytix, Inc is a biotechnology company focused on using its core bacteriophage/phage technology platform to improve human health through the development and commercialization of innovative products for food safety, veterinary applications and human therapeutics and probiotics.

For more information, contact Mr. John Woloszyn (410-625-3813 or jwoloszyn@intralytix.com) or Dr. Barbara Miller (513-622-4350 or miller.be@pg.com).